High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

References

• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851–2857. doi:10.1200/JCO.2015.66.2866
   PubMed Web of Science ®Google Scholar
• Sukegawa M, Wang X, Nishioka C, et al. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. Leuk Res. 2017;58:83–90. doi:10.1016/j.leukres.2017.05.005
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160–1178. doi:10.1016/j.jacc.2015.07.025
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347–1348. doi:10.1093/jnci/djr292
   PubMedGoogle Scholar
• Kim TD, Le Coutre P, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. haematologica. 2012;97(6):883–889. doi:10.3324/haematol.2011.058776
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300–1310. doi:10.3109/10428194.2015.1091929
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–4218. doi:10.1200/JCO.2015.62.4718
   PubMed Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105(48):18895–18900. doi:10.1073/pnas.0810246105
   PubMed Web of Science ®Google Scholar
• Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med. 2005;352(10):1049–1050. doi:10.1056/NEJM200503103521023
   PubMed Web of Science ®Google Scholar
• Giles F, Mauro M, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–1315. doi:10.1038/leu.2013.69
   PubMed Web of Science ®Google Scholar
• Valent P, Hadzijusufovic E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901–906. doi:10.1182/blood-2014-09-594432
   PubMed Web of Science ®Google Scholar
• Kim T, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27(6):1316–1321. doi:10.1038/leu.2013.70
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kim D-W, Pinilla-Ibarz J, et al. 2014; Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial. J Clin Oncol. 2014 32:15_suppl, 7081-7081
   Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17):2128–2137. doi:10.1161/CIRCULATIONAHA.111.079921
   PubMed Web of Science ®Google Scholar
• Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293–303. doi:10.2147/VHRM.S108874
   PubMed Web of Science ®Google Scholar
• Breccia M, Pregno P, Spallarossa P, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96(4):549–558. doi:10.1007/s00277-016-2820-x
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi:10.1182/blood-2013-05-501569
   PubMed Web of Science ®Google Scholar
• Hadi HA, Carr CS, Suwaidi A. J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183.
   PubMedGoogle Scholar
• Gopal S, Lu Q, Man JJ, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2(14):1680–1684. doi:10.1182/bloodadvances.2018020396
   PubMed Web of Science ®Google Scholar
• Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31(11):2388–2397. doi:10.1038/leu.2017.245
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation. 2008;117(6):743–753. doi:10.1161/CIRCULATIONAHA.107.699579
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi:10.1016/S0140-6736(04)17018-9
   PubMed Web of Science ®Google Scholar
• Corlin L, Liu C, Lin H, et al. Proteomic signatures of lifestyle risk factors for cardiovascular disease: a cross-sectional analysis of the plasma proteome in the Framingham heart study. J Am Heart Assoc. 2021; Jan 510(1):e018020.
   PubMed Web of Science ®Google Scholar
• Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol. 2006; 24(33):5216–5222. doi:10.1200/JCO.2006.07.1381
   PubMed Web of Science ®Google Scholar
• Ching C, Gustafson D, Thavendiranathan P, et al. Cancer therapy-related cardiac dysfunction: is endothelial dysfunction at the heart of the matter? Clin Sci (Lond). 2021;135(12):1487–1503. doi:10.1042/CS20210059
   PubMed Web of Science ®Google Scholar
• Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci (Lond). 2011;120(9):357–375. doi:10.1042/CS20100476
   PubMed Web of Science ®Google Scholar
• Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133(14):1597–1606. doi:10.1182/blood-2018-10-881557
   PubMed Web of Science ®Google Scholar
• Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021; 37(8):1129–1150. doi:10.1016/j.cjca.2021.03.016
   PubMed Web of Science ®Google Scholar
• Shao Y, Saredy J, Yang WY, et al. Vascular endothelial cells and innate immunity. Arterioscler Thromb Vasc Biol. 2020;40(6):e138–e152. doi:10.1161/ATVBAHA.120.314330
   PubMed Web of Science ®Google Scholar
• Gustafson D, Fish JE, Lipton JH, et al. Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Hematol Malig Rep. 2020;15(1):20–30. doi:10.1007/s11899-020-00560-x
   PubMed Web of Science ®Google Scholar
• Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58(6):1455–1467. doi:10.1080/10428194.2016.1239258
   PubMed Web of Science ®Google Scholar
• Sicuranza A, Ferrigno I, Abruzzese E, et al. Pro-Inflammatory and Pro-Oxidative changes during nilotinib treatment in CML patients: results of a prospective multicenter Front-Line TKIs study (KIARO study). Front Oncol. 2022;12:835563. doi:10.3389/fonc.2022.835563
   PubMed Web of Science ®Google Scholar
• Leong D, Aghel N, Hillis C, et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart. 2021;107(8):667–673. doi:10.1136/heartjnl-2020-318251
   PubMed Web of Science ®Google Scholar
• Aghel N, Lipton JH, Atenafu EG, et al. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk. 2017; 17(12):870–878.e1. doi:10.1016/j.clml.2017.07.006
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9):1135–1143. doi:10.1161/hc0902.104353
   PubMed Web of Science ®Google Scholar
• Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022; 108(1):73–79. doi:10.1136/heartjnl-2019-316378
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565. doi:10.1056/NEJMoa021993
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646
   PubMed Web of Science ®Google Scholar
• Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi:10.1161/CIRCULATIONAHA.115.020406
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137–144. doi:10.1038/s41569-019-0247-5
   PubMed Web of Science ®Google Scholar
• Manouchehri A, Kanu E, Mauro MJ, et al. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. Arterioscler Thromb Vasc Biol. 2020;40(2):301–308. doi:10.1161/ATVBAHA.119.313353
   PubMed Web of Science ®Google Scholar
• Collaboration ERF. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet. 2010;375(9709):132–140.
   PubMed Web of Science ®Google Scholar
• Gimbrone MA, Jr, García-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol. 2013;22(1):9–15. doi:10.1016/j.carpath.2012.06.006
   PubMed Web of Science ®Google Scholar
• Sattar N, McCarey DW, Capell H, et al. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957–2963. doi:10.1161/01.CIR.0000099844.31524.05
   PubMed Web of Science ®Google Scholar
• Pouwer MG, Pieterman EJ, Verschuren L, et al. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med. 2018;5:55. doi:10.3389/fcvm.2018.00055
   PubMed Web of Science ®Google Scholar
• Paez-Mayorga J, Chen AL, Kotla S, et al. Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation. Front Cardiovasc Med. 2018;5:125. doi:10.3389/fcvm.2018.00125
   PubMed Web of Science ®Google Scholar
• Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017 Feb 15;9(377):eaaf2584. doi:10.1126/scitranslmed.aaf2584. PMID: 28202772; PMCID: PMC5409837
   Google Scholar